目的：分析玻璃体切除联合白内障超声乳化吸出术对玻璃体视网膜疾病合并白内障患者的治疗效果。

方法：选取2014-01/2016-11在本院接受治疗的玻璃体视网膜疾病合并白内障患者150例，依据随机数字表法将患者分成两组：联合组(75例)采用玻璃体切除联合白内障超声乳化吸出术； 对照组(75例)先进行玻璃体切除术，再进行白内障超声乳化吸出术。术后随访6mo，观察患者视力恢复和眼轴长度变化情况，记录术后并发症情况。

结果：治疗后两组患者视力≥0.1人数均有明显提高，与治疗前对比差异均有统计学意义(P<0.05)，且联合组患者比例为95%，高于对照组的63%，差异有统计学意义(P<0.05)； 两组患者手术前后眼轴长度均无明显变化，同组治疗前后及组间对比差异均无统计学意义(P>0.05)； 联合组患者屈光度向近视发生偏移，对照组屈光度向远视发生偏移，两组预测数值对比差异无统计学意义(P>0.05)，实际数值对比差异有统计学意义(P<0.05)； 联合组患者出现并发症比例为24%，低于对照组(40%)，差异有统计学意义(P<0.05)。

结论：玻璃体切除联合白内障超声乳化吸出术对玻璃体视网膜疾病合并白内障患者疗效显著，且安全性好，临床应用价值较高。

METHODS: A total of 150 patients with vitreoretinal disease and cataract were treated in our hospital from January 2014 to November 2016. According to the random number table method they were divided into two groups: combination group(75 cases)with vitrectomy combined with phacoemulsification, the control group(75 cases)with vitrectomy first, then phacoemulsification surgery. The recovery of visual acuity and the change of the axial length of the eyes were observed. The patients were followed up for 6mo, and the postoperative complications were recorded.

RESULTS: After treatment, number of patients in the two groups with visual acuity ≥0.1 were significantly improved compared with before treatment(P<0.05), and the percent in combination group was 95%, higher than 63% in the control group(P<0.05). There were no significant changes in the axial length before and after the operation in the two groups(P>0.05), and there was no significant difference between the groups before and after treatment(P>0.05). The refractive status of combination group shifted to myopia, that of control group shifted to hyperopia, two groups had no statistically significant difference on numerical prediction(P<0.05). The difference was statistically significant on the actual values(P<0.05). The complication rate in the combination group was 24%, which was lower than 40% in the control group, and the difference was statistically significant(P<0.05).

CONCLUSION: Vitrectomy combined with phacoemulsification on vitreoretinal diseases with cataract patients is effective, and safety, clinical application value is higher.